Keylika Analysis
What is Keylika?
Keylika develops innovative transdermal drug delivery systems, focusing on a skin patch for treating iron deficiency anemia, combining oral and IV iron benefits without side effects.
Employees
1
Founded
2022
Investors
- Y Combinator
- Fundament
Product Features & Capabilities
- Custom transdermal iron patch (NistuFe) for iron deficiency anemia, new molecular entity (KYLK01), small molecule (< 500 Da), better absorption, no gastrointestinal side effects, higher bioavailability, self-administrable, low risk, NistuHeal skin cream solution.
Who are the founders of Keylika
BP
Buddhadev P. Chaudhuri
CEO & Co-Founder
FC
Frederik Ceyssens
CTO & Co-Founder
Business Model
Focuses on drug delivery innovation; revenue from product sales and partnerships.
Competitors Overview
Keylika operates in the drug discovery and delivery market, focusing on innovative therapies using AI and nanotechnology. Its main competitors include:
- Exscientia: A pioneer in AI-driven drug discovery, Exscientia utilizes machine learning to design and develop drugs more efficiently. Their
Market Focus
Keylika primarily focuses on the pharmaceutical industry, specifically in drug discovery and delivery, utilizing AI and nanotechnology to develop innovative therapies, including a transdermal patch for treating iron deficiency anemia.
See something that needs updating? Suggest edits to this profile.